Exane Boosts PT on Autoliv (ALV) to $131; Will Benefit from Takata 'Misfortune'

Autoliv (NYSE: ALV) may see additional upside stemming from the recent Takata airbag recall.

Exane sees Autoliv shares gaining 26 percent from additional business tied to the misfortune. The gains should also help to offset negative foreign exchange impacts, which is expected to have a negative 4 percent impact on 2015 EBIT expectations.

Exane is raising its price target on Outperform-rated Autoliv from $118 up to $131 on the speculation. The firm sees Autoliv buybacks at 9 percent of market cap this year and over 20 percent within the next three years.

For an analyst ratings summary and ratings history on Autoliv, Inc. click here. For more ratings news on Autoliv, Inc. click here.

Autoliv, Inc. closed at $103.57 yesterday.

You May Also Be Interested In

• Sage Therapeutics (SAGE) PT Lowered to $17 at Oppenheimer
• Travelers (TRV) PT Lowered to $202 at Goldman Sachs
• Travelers (TRV) PT Lowered to $214 at Morgan Stanley